Drug Delivery Partnership Strategies

No single drug delivery partnership model can be applied across all drug delivery partnerships. Partnering around drug delivery technology can occur at different stages of the drug development and commercialization lifecycle, requiring varying levels of collaboration and involving multiple different partners and their respective interests.

The degree of intended collaboration between drug delivery technology partners has declined over the past five years. Big pharma has become an increasingly important source for high value licensing investment in novel drug delivery technologies.

This report builds on interviews with industry executives, case studies, and analysis of deal and other market data to set out a set of strategies to optimally partner for enhanced drug delivery products.

Features and benefits
•    Learn from interviews with senior drug delivery partnering executives.
•    Develop effective partnering strategies based on case studies and analysis of market data.
•    Unlock therapeutic value of new biopharmaceutical developments by strategic collaborations for innovative drug delivery technologies.
•    Optimise value from drug delivery partnerships to deliver successful differentiation from novel drug delivery applications.
•    Understand current and future trends in drug delivery deal-making in order to plan effective partnering strategy.

Drug Delivery Partnership Strategies Report

Published: March 2012
No. of Pages: 101
Price: Single User License: US$3835         Corporate User License: US$14381
                               

Your key questions answered
•    How is the drug delivery partnering landscape changing and how will this affect future deal-making?
•    What are the key strategic contexts for effective drug delivery partnering and how do these impact on deal parameters?
•    What are the critical success factors involved in lifecycle management deal-making for drug delivery technology?
•    What are the key challenges involved with making effective drug delivery partnerships for novel drug delivery applications?
•    How do best practices for drug delivery partnerships differ by the degree to which the delivery component of a drug contributes to its overall value?

Major points covered in Table of Contents of this report include:
EXECUTIVE SUMMARY
An introduction to drug delivery partnerships
The drug delivery value chain
Partnering trends in drug delivery technology
Drug delivery partnerships for lifecycle management
Drug delivery partnerships for complex development compounds
Best practices for effective drug delivery partnering
Appendix
List of Tables
List of Figures

Explore reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/
                              

Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, “Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Gaucher's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Gaucher's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gaucher's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/144564-gauchers-disease-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html

Scope
The report provides information on the key drivers and challenges of the Gaucher's Disease Therapeutics market. Its scope includes -
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gaucher's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Gaucher's Disease Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gaucher's Disease Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Gaucher's Disease Therapeutics market

Gaucher's Disease Therapeutics Market

Report Details:
Published: January 2012
No. of Pages: 66
Price: Single User License – US$3500              Corporate User License – US$10500

                                         

               

Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/144351-hepatitis-market-to-2017-strong-hepatitis-c-pipeline-large-number-of-strategic-consolidations-and-cost-effective-treatments-will-drive-the-market.html

Scope
• Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.
• Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.
• Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
• Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
• Key drivers and barriers that have a significant impact on the market.
• Coverage of pipeline molecules in various Phases of drug development.
• Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
• Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.

Fabry’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, “Fabry’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Fabry's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Fabry's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Fabry's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/144147-fabrys-disease-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html

Scope
The report provides information on the key drivers and challenges of the Fabry's Disease Therapeutics market. Its scope includes -
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Fabry's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Fabry's Disease Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Fabry's Disease Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Fabry's Disease Therapeutics market

Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, “Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Sickle Cell Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Sickle Cell Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sickle Cell Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope
The report provides information on the key drivers and challenges of the Sickle Cell Anemia Therapeutics market. Its scope includes –
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sickle Cell Anemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Sickle Cell Anemia Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sickle Cell Anemia Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Sickle Cell Anemia Therapeutics market

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/144146-sickle-cell-anemia-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html.

Baxter International Inc.: PharmaVitae Report

Strategic insight into the prospects for Baxter over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/144099-baxter-international-inc-pharmavitae-report.html

Features and benefits
• Gain insight into Baxter's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Major points covered in Table of Contents of this report include:
• EXECUTIVE SUMMARY
• STRATEGIC INSIGHT
• COMPANY INTRODUCTION
• SALES ANALYSIS
• FINANCIAL ANALYSIS
• PRODUCT ANALYSIS
• APPENDIX
• Tables and Figures

Explore Comprehensive list of more than 40 Tables & Figures available in the report Baxter International Inc.: PharmaVitae Report.

Warner-Chilcott Plc: PharmaVitae Report

This analysis Warner-Chilcott Plc: PharmaVitae Report examines the historical and forecast performance for Warner-Chilcott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
• Gain insight into Warner-Chilcott's strategic outlook across the next 6 years.
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Browse All: Pharmaceuticals Market Research

Table Of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Key findings
Warner Chilcott prescription pharma sales outlook
Warner Chilcott financial outlook
SWOT analysis
Weaknesses
Opportunities
Threats

STRATEGIC INSIGHT
Proctor & Gamble acquisition will shape performance through to 2016
Portfolio has undergone substantial change
Impact of expiries increased by narrower product focus
Patent expiries non-negotiable – pre-erosion cash flow critical to future expansion
P&G acquisition will drive superior operating performance…
and provide platform for further diversification and strategic evolution

COMPANY INTRODUCTION
Background
M&A history

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 78
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global Polycystic Ovarian Syndrome Therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of the unavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patient satisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility, hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern with the help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants are institutions or universities. Company participation is very low because most of the drugs which are under trial are generics and already being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact the market significantly.

Scope
The report provides information on the key drivers and challenges of the PCOS market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen, Progesterone derivative, Oral contraceptives, Antiobesity drugs and others.
- Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt. Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutic market.
- Analysis of key recent licensing and partnership agreements in PCOS market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PCOS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global PCOS market landscape? – Identify, understand and capitalize.

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 83
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global FM market. The report identifies the key trends shaping and driving the global FM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global FM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.4 billion by 2018. The restricted growth in the market is due to the unavailability of approved drugs in the EU and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of newer therapies in late stage FM therapeutics pipeline. Currently, FDA (Food and Drug Administration) has approved three drugs for the treatment of FM. Lyrica (pregabalin) was the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and Savella (milnacipran) in January 2009. Marketing authorization of these drugs has been rejected by EMEA (European Medical Agency) due low effectiveness and high adverse reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in 2008, followed by Lyrica in 2009 and Savella in 2010. However, increasing prevalence and diagnosis is expected to drive the future FM therapeutic market.

Scope

The report provides information on the key drivers and challenges of the FM market. Its scope includes - 

- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as therapies based on SSRI and GABA agonist calcium channel blocker, sodium channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.

- Analysis of the current and future competition in the global FM market. Key market players covered are the Pfizer, Jazz Pharmaceuticals and UCB.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the FM therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global FM market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global FM market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global FM market landscape? – Identify, understand and capitalize.

GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing

Published: November 2011
No. of Pages: 143
Price: $ 3500

A superfamily of diverse transmembrane receptors, GPCRs help in the activation of cellular responses by interacting with molecules outside the cell. These molecules are known as ligands. The cellular responses are activated through a system of signaling pathways, called as signal transduction pathways. Human genome sequencing has helped us to understand the importance of these diverse classes of receptors, with about 1,000 sequences identified to be GPCRs. About 400 GPCRs bind with endogenous ligands; however such ligands have not been discovered for about 33% of all GPCR targets, thus emphasizing on the potential these receptors have as targets for future drug discovery.

Novel Research Methods are Being Employed to Identify and Develop Products that Target GPCRs More Effectively

The understanding of GPCR biology was limited for a very long time, although researchers were successful in identifying many GPCR targets using genomic approaches. However, there was no real understanding of the receptor structure-function relationship, and how different signaling molecules activated these receptors. Hence, the goal was to find the endogenous and/or exogenous ligands that paired with each GPCR, which could help the discovery of new avenues in therapy and de-orphanization of GPCRs. However, there are still more than 100 orphan GPCRs for which ligands have not yet been identified. This coupled with the fact that only about 30% of the 800 odd GPCRs have been targeted so far by currently marketed medicines leads to the conclusion that GPCR research has immense potential to bring out new therapies. Basic research advances concerning receptor X-ray structures, allosteric interactions and functional selectivity have opened the way for further exploitation of this large and diverse class of targets.

Research and Development Efforts in the Area of GPCRs will be Concentrated, Especially on De-Orphanization of Orphan GPCRs

Some of the new GPCRs discovered, especially those discovered through sequence homology, had one basic problem in that the endogenous ligands that bind to these receptors could not be identified. Hence, such receptors without any endogenous ligands were termed orphan GPCRs. One would think that functional activity of orphan GPCRs would be questioned as there are no known ligands that bind to these receptors, however expression of these orphan receptors in many different species accounts for their functional activity. Discovery of ligands that target orphan GPCRs is proving to be an extremely challenging task for researchers and for pharmaceutical and biotechnology companies all over the world. With the number of new molecules that get approval from the regulatory authorities falling drastically, coupled with the arrival of a patent cliff for the next four to five years, researchers are looking at the super-family of GPCRs with more interest than ever before. One of the most important segments of GPCR research concentrates on de-orphanizing GPCRs, identifying unknown ligands and establishing functional activity for orphan receptors.

Pipeline Analysis of Molecules Reveals the Central Nervous System, Oncology and Cardiovascular System to be the Most Targeted Therapeutic Classes

There are many programs looking at the role of GPCRs in obesity, the role of GPCRs in pain states, and in controlling tumorigenesis. A large number of CNS diseases involve GPCRs, ranging from depression to neurodegenerative diseases such as Alzheimer's disease, and they are therefore looked at in both the peripheral and the central nervous system. Many research papers defining receptor pharmacology use the brain for ligand-binding experiments. Modern research labs continue to study receptor pharmacology in brain tissue. There may be a preponderance of work on GPCRs in CNS because of this history, but there are lots of opportunities to progress GPCR therapeutics in many other areas.

Report overview

This report GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most important category of receptors in the human body. The report provides a scientific understanding of GPCRs and details the novel research methods being employed in the research of new targets and molecules that can be more effective in treating many indications. A special note on Orphan GPCRs and ways to de-orphanize them is followed by a detailed pipeline analysis to understand the therapeutic classes and indications that are being targeted through GPCRs. The report provides an in-depth analysis of the competitive landscape, including the profiling of top companies and licensing agreements involving GPCR molecules and platform technologies.

Browse All: Pharmaceuticals Market Research

Scope

The scope of this report includes -

• Detailed technical understanding of G protein coupled receptors

• Dedicated sections on Novel research methods being used to improve the GPCR targeted drug discovery and development process

• Understanding of Orphan GPCRs, its importance and novel methods to locate ligands and de-orphanize these receptors

• Pipeline analysis of products at various stages of development targeting receptors classified as GPCRs, including identification of major therapeutic areas and indications

• Analysis and review of important strategic partnerships and licensing agreements in the area of GPCR drug discovery and development

• The report also covers information on the leading market players and the competitive landscape, including specialist companies which have proprietary GPCR platform technology as well as major companies with molecules in not only the NDA Filed stage but also in Phase III

Reasons to buy

The report GPCRs in Drug Discovery will enhance your decision making capability. It will allow you to -

• Develop business strategies by understanding the trends shaping and driving research in the field of GPCRs

• Understand the potential areas of application for GPCR therapies.

• Identify key molecules targeting GPCRs in development based on the therapy.

• Identify the key players investing in GPCR platform technologies

• Optimize your R&D pipeline through identification of novel technologies being used in GPCR research to improve the drug discovery process

• Identify emerging players with a potentially strong product portfolio of molecules targeting GPCRs and create effective counter-strategies to gain a competitive advantage.

• What's the next big thing in GPCR research? – Identify, understand and capitalize.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 126
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global ADHD therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010, three drugs namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) were approved in the US. The acceptance for Vyvanse was high in the US, in spite of its high treatment cost in comparison to that of existing drugs. Thus, high acceptance for Vyvanse has resulted in the significant growth of the market. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, due to which the US market declined. This has resulted in the decline in the global ADHD market in 2009.

Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but it is slightly high in Japan (18.4%). This difference across geographical markets exists because of the variation in the approval date for some of the drugs in the US, Europe and Japan. In the US, major nonstimulant therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved; whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse, being a safer nonstimulant, its acceptance across Europe would be high and considered as growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have similar therapeutic mode of action as that of exiting drugs which will not impact the market significantly.

During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the losses due to expiry of these patents would be compensated by new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will show a steady growth from 2010 to 2018.

Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitor, selective alpha2A-adrenergic receptor agonist, serotonin-norepinephrine-dopamine reuptake inhibitor, selective serotonin (5-HT1)-dopamine antagonist, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitor (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonist, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonist, alpha7 NNR agonist., serotonin and norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonist, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonist, histamine H3 receptor antagonist, selective alpha2A-adrenergic receptor agonist, histamine H3 autoreceptor antagonist, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitor, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonist.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 147
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The bisphosphonates are the preferred drug for treatment and are used as the first line of therapy for the treatment of osteoporosis. The expected moderate growth can be attributed to the increase in awareness among people regarding osteoporosis, especially among females about postmenopausal osteoporosis (PMO) which contributes the largest number of patient pool to osteoporosis. GlobalData also predicts that an increase in the patient population as a consequence of the ageing population will drive the moderate growth in the osteoporosis therapeutics market. The modest growth observed in the osteoporosis therapeutics market during 2010 to 2018 can also be attributed to the expected launch of pipeline products such as Odanacatib (MK 0822), NB S101 during the late forecast period. The patent expiry of Actonel (risedronate sodium), Boniva (ibandronate), Reclast (zoledronic acid), Evista (raloxifene) and Protelos (strontium malonate) during 2012 to 2014 will act as the major barriers for the growth of osteoporosis therapeutics market during the forecast period. The impending patent expiry of Boniva in 2012; Actonel and Reclast in 2013; and Evista in 2014 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The sales growth will also be affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.

Scope

The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes - 

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor

- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global osteoporosis therapeutics market landscape? – Identify, understand and capitalize.

Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011

No. of Pages: 105

Price: $ 3500

 GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes - 

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.

- Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals,LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global osteoarthritis therapeutics market landscape? – Identify, understand and capitalize.

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 98
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global growth hormone deficiency therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global growth hormone deficiency therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global growth hormone deficiency sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global GHD therapeutics market values $1,354.5m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 4.0% during 2005–2010. However, the market is expected to record a CAGR of 3.7% from 2010–2018, to value $1,804.7m by 2018. The growth recorded in GHD therapeutics market during 2005-2010, was primarily attributed to increase in the annual cost of therapy with the existing treatment options available. Apart from this, there are limited numbers of biosimilars formulation such as Omnitrope (somatropin), Valtropin (somatropin) in GHD therapeutics market. The launches of biosimilars have modest impact on the GHD therapeutics market because of availability of these products present at a competitive price. The Omnitrope was approved by the US Food and Drug Administration (US FDA) after long delays and court proceedings.

Scope
The report provides information on the key drivers and challenges of the growth hormone deficiency therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) growth hormone deficiency therapeutics market revenue data for 2005–2010, and 2011–2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidate’s fall under the therapy classes such as immunomodulator, anti-CD3 antibody, oral Insulin analogue, GLP-1 receptor agonist, interleukin-1 inhibitor, ultra-long acting insulin analogue, ultra-fast-acting insulin analogue, Insulin analogue and ultra rapid-acting insulin analogue.
- Analysis of the current and future competition in the seven key countries of the growth hormone deficiency therapeutics market. LG Life Sciences, BioPartners GmbH, Roche Group, Pfizer, Novo Nordisk, Astrazeneca, Ascendis Pharma A/S, Ipsen S.A., EMD Serono, Inc., Theratechnologies Inc, Eli Lilly and Company and Ambrx, Inc.they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the growth hormone deficiency therapeutics market.
- Analysis of key recent licensing and partnership agreements in growth hormone deficiency therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global growth hormone deficiency therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global growth hormone deficiency therapeutics market landscape? – Identify, understand and capitalize.

Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 105
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global Heart Failure therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global Heart Failure therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Heart Failure sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in 2015. An increase in the treatment seeking population due to an increase in the life expectancy and increasing awareness leading to diagnosis at an early stage will also drive the HF therapeutics market. Apart from these the HF therapeutics market will be driven by the increases in aging population which are more susceptible towards Acute Heart Failure (AHF). The current competition in the HF therapeutics market is weak, primarily dominated by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace (ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded product which are expected to lose patents in 2012 and 2014 respectively.

Browse All: Pharmaceuticals Market

Scope
The report provides information on the key drivers and challenges of the Heart Failure therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.
- The late stage pipeline has molecules which would affect progression of HF, known as renin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acute case of heart failure. The other promising drugs in the HF developmental pipeline in terms of mechanism of action include a stem cell therapy, angiotensin converting enzyme inhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-like peptide 1 agonist.
- Analysis of the current and future competition in the key countries of the Heart Failure therapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics, and GlaxoSmithKline are the key players, they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Heart Failure therapeutics market.
- Analysis of key recent licensing and partnership agreements in Heart Failure therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Heart Failure therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global Heart Failure therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Heart Failure therapeutics market landscape? – Identify, understand and capitalize.

Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 87
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global brain hemorrhage therapeutics market. The report identifies the key trends shaping and driving the global brain hemorrhage therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global brain hemorrhage therapeutics market was valued at $358m in 2010 and forecasts to grow at a Compound Annual Growth Rate (CAGR) of 3% over the next eight years, to reach $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to the stable prevalence, high mortality and weak pipeline with only two company sponsored drugs in the pipeline. Life style factors such as smoking, obesity and alcohol are the major risk factors associated with brain hemorrhage. The existing market does not have any approved therapies and the off-label drugs such as antihypertensive agents (labetalol and nicardipine), hemostatic agents (vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy (mannitol 20%) are the most commonly prescribed therapies. These treatment options offer symptomatic treatment. These drugs/ therapies lack superior safety and efficacy. These factors would result in slow growth of the global brain hemorrhage therapeutics market through 2018.

GlobalData has found that the brain hemorrhage therapeutics market has high unmet needs, suggesting that the current market is not well served by the current treatment options. Moreover, these treatment options are not approved and are used as off-label. The market is dominated by off-label and generic medications which include antihypertensive agents, hemostatic agents, antiepileptic agents, and osmotherapy. Absence of approved therapies for brain hemorrhage clearly establishes that the current brain hemorrhage therapeutics market has high unmet need and there is scope for new entrants exhibiting superior safety and efficacy

Browse All: Pharmaceuticals Market Research Reports

Scope
The report provides information on the key drivers and challenges of the brain hemorrhage therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) brain hemorrhage market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Most of the clinical trials are conducted by academic institutions, currently only GLP-1 CellBeads and PG2 are the drugs sponsored by CellMed AG/BTG and PhytoHealth Corporation respectively. Of the total number drugs in the pipeline, four drugs are first-in-class and the remaining 12 drugs are generics. The mechanism of action of one drug in phase 0 is unknown. The first-in-class molecules have a distinct advantage over the currently marketed products with regards to better symptomatic management.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the brain hemorrhage therapeutics market.
- Analysis of key recent licensing and partnership agreements in brain hemorrhage therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global brain hemorrhage therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global brain hemorrhage therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global brain hemorrhage therapeutics market landscape? – Identify, understand and capitalize.

Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 115
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global bipolar disorder market. The report identifies the key trends shaping and driving the global bipolar disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bipolar disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global bipolar disorder therapeutics market was valued at $6,242m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.0% over the next eight years, to reach $7,340m by 2018. Atypical antipsychotics, mood stabilizers, and antidepressants are the commonly prescribed drugs for the treatment of bipolar disorder. The slow market growth during the forecast period is attributed to the patent expiry of leading drugs, the entry of new drugs, and stable prevalence. The bipolar disorder therapeutics market will witness the patent expiry of leading drugs such as Zyprexa (2011 in the US and Europe, 2015 in Japan), Seroquel (2012), Geodon/Zeldox (2012), Abilify (2014 in Europe, 2015 in the US and 2017 in Japan), and Sapharis/Sycrest (2015). In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar disorder therapeutics market through 2018.

During 2000-2005, several drugs were approved for the treatment of bipolar disorder, such as Abilify (aripiprazole), Geodon/Zeldox (ziprasidone), Lamictal (lamotrigine), Risperdal (risperidone), Seroquel (quetiapine), Symbyax (olanzapine and fluoxetine combination) and Zyprexa (olanzapine). Increased uptake of these approved drugs resulted in a relatively high growth of the market through the historic period 2005-2010.

Browse All: Pharmaceuticals Market Research

Scope
The report provides information on the key drivers and challenges of the bipolar disorder market. Its scope includes -
- Annualized data on seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for bipolar disorder revenue from 2005 to 2010, with forecasts to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed, and emerging trends. Pipeline candidates fall under major therapeutic classes such as dopamine and serotonin receptor antagonist, selective serotonin reuptake inhibitor (SSRI), sodium channel blocker, N-methyl D-aspartate (NMDA) receptor antagonist, partial agonist at dopamine and serotonin receptor, dopamine D3/D2 partial agonist, analeptic activity, ion channel blocker, selective serotonin reuptake enhancer, NMDA Receptor modulator, muscarinic receptor antagonist, deoxyribonucleic acid (DNA) polymerase inhibitor, microglial activation inhibitor, xanthine oxidase inhibitor, ion channel blocker and NMDA antagonist, opoid antagonist, glutamate inhibitor, mood stabilizer, acting on depression and anxiety related central nervous system (CNS) receptors, anti-psychotic, and stimulating the release of norepinephrine.
- Analysis of the current and future competition in the global bipolar disorder market. Key market players covered are Alexza Pharmaceuticals, Gedeon Richter, Dainippon Sumitomo Pharma and Cephalon.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bipolar disorder therapeutics market.
- Analysis of key recent licensing and partnership agreements in the bipolar disorder market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bipolar disorder market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global bipolar disorder market landscape? – Identify, understand and capitalize.

Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 114
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global tuberculosis infection market. The report identifies the key trends shaping and driving the global tuberculosis infection market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global tuberculosis infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.


Browse All: Pharmaceuticals Market

The global Tuberculosis (TB) infection market was worth $38.3m in 2010. The market is expected to decline at a compound annual growth rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have been improved with the conventional DOTS (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB with lesser treatment duration. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is heading towards a phase of decline as no launches are expected until 2018. Further the prevalent and reported TB cases have also reduced due to increased access to the DOTS and DOTS-PLUS programs in developed countries.

Scope
The report provides information on the key drivers and challenges of the tuberculosis infection market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) tuberculosis infection market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as vaccines, antimycobacterial agent, oxazolidinones, DNA-dependent RNA polymerase inhibitor, T-Cells stimulator, synthetic fluoroquinolone antibacterial agent, immunosuppressant, mycolic acid biosynthesis inhibitor, nitroimidazo-oxazine anti-bacterial agents, mycobacterial ATP synthase inhibitor, DNA synthesis inhibitors, cell wall synthesis inhibitor, dipiperidine antibiotic, translocase 1 (TL-1) inhibitors, lipid peroxidation inhibitor, proteasome inhibitors, non metabolized glucose analogue.
- Analysis of the current and future competition in the seven key countries tuberculosis infection market. Key market players covered are ActivBiotics Pharma, Aeras Global TB Vaccine Foundation, Archivel Farma S.L., AstraZeneca PLC, Bayer, GlaxoSmithKline, Imaxio, Immunitor USA Inc., Novartis, Pfizer, Sanofi, Sequella, Inc., Tibotec BVBA (Subsidery of J&J).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the tuberculosis infection therapeutics market.
- Analysis of key recent licensing and partnership agreements in tuberculosis infection market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global tuberculosis infection market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global tuberculosis infection market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global tuberculosis infection market landscape? – Identify, understand and capitalize.

Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 69
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global sarcopenia therapeutics market. The report identifies the key trends shaping and driving the global sarcopenia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global sarcopenia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Global Data estimates that the global sarcopenia therapeutics market was valued at $10.1m in 2010. The market is forecasted to witness a consistent growth with a Compound Annual Growth Rate (CAGR) of 9.6% in the next eight years and it is expected to reach $20.9m in the year 2018. This is inclusive of the markets of the US, the UK, Italy and Japan. The growth in the market is primarily attributed to increases in aging populations. The limited valuation of the market is due to the fact that drug therapy is not recommended as the first line treatment for sarcopenia. At present, no drug has been approved for treating sarcopenia. The current competitive landscape consists of only generic and off-label drugs such as testosterone, estrogen and growth hormones. In countries such as Germany, Spain and France, no pharmacological treatment is being prescribed for treating sarcopenia so these countries were not included when estimating the global sarcopenia therapeutics market. The treatment landscape is not going to witness any major change in the future due to lack of promising drugs in the late stage pipeline. The global sarcopenia market is expected to remain as a low value market during the forecast period due to the domination of off-label drugs.

Browse All: Pharmaceuticals Market Research

Scope

The report provides information on the key drivers and challenges of the sarcopenia therapeutics market. Its scope includes - 

- Annualized global sarcopenia therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as androgen and growth hormones.

- Analysis of the current and future competition in the global sarcopenia therapeutics market. The key market player covered is GTx.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the sarcopenia therapeutics market.

- Analysis of key recent licensing and partnership agreements in sarcopenia theapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global Sarcopenia therapeutics market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sarcopenia therapeutics market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global Sarcopenia therapeutics market landscape? – Identify, understand and capitalize.

S-1 (Cervical Cancer) – Analysis and Forecasts to 2020

Published: October 2011
No. of Pages: 23
Price: $ 2000


GlobalData’s pharmaceuticals report, “ S-1 ( Cervical Cancer) - Analysis and Forecasts to 2020” provides S-1 sales forecasts for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Browse All: Pharmaceuticals Market Research Reports

Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of S-1 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of S-1 including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2015-2020 for S-1 in Japan

Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets